Email this article 
Hide
Show all
Original Research
Localised treatment and 6-month outcomes in patients with cytomegalovirus retinitis at a tertiary ophthalmology service in Ga-Rankuwa
Southern African Journal of HIV Medicine | Vol 13, No 2 | a141 |
DOI: https://doi.org/10.4102/sajhivmed.v13i2.141
| © 2012 Fatima Laher, Claire Cullen, J Baile Matlala
| This work is licensed under CC Attribution 4.0
Submitted: 15 December 2012 | Published: 07 June 2012
Submitted: 15 December 2012 | Published: 07 June 2012
About the author(s)
Fatima Laher, Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South AfricaClaire Cullen, Department of Ophthalmology, Dr George Mukhari Hospital, Ga-Rankuwa, Gauteng
J Baile Matlala, Department of Ophthalmology, Dr George Mukhari Hospital, Ga-Rankuwa, Gauteng
Abstract
Objective. There are few data from before the antiretroviral therapy (ART) era for cytomegalovirus retinitis (CMV-R) from settings where cost limits use of systemic treatment. This study examines CMV-R treatment and survival outcomes in a public hospital ophthalmology service in Ga-Rankuwa, South Africa.
Methods. From October 2009 to October 2010, voluntarily consenting participants over the age of 15 years with incident clinically diagnosed CMV-R seen at the Dr George Mukhari Hospital ophthalmology clinic were prospectively enrolled in an observational study. Treatment was per clinic protocols and patients were followed up with structured data collection for up to 6 months.
Results. Eight individuals, all HIV infected and 50% female, were identified and enrolled. At enrolment, median age was 38 years (interquartile range (IQR) 32 - 39 years), median CD4 count 20 cells/μl (IQR 13 - 46.5 cells/μl), and 50% were currently receiving ART (mean duration of ART use 18 days, standard deviation (SD) 2.99 days). No participant received systemic ganciclovir, but 6 reported symptom combinations suggesting systemic CMV: shortness of breath (n=3), diarrhoea (n=3) and/or central nervous system complaints (n=3). Ten eyes had visual impairment less than counting fingers at enrolment. Treatment combinations were: ART plus intravitreal ganciclovir (n=5), intravitreal ganciclovir alone (n=2), and ART alone (n=1). Six-month outcomes were: death (n=1), survival (n=6), loss to follow-up (n=3), untraceable (n=1), systemic symptom resolution (4/4), visual acuity deterioration (0/5), and persisting uveitis (2/3).
Conclusion. In the ART era, incident CMV-R appears to be uncommon in this setting. CMV-R may occur within the first 3 weeks after ART initiation. Even in CMV-R patients with suggestive systemic symptoms, 6-month survival is good despite no systemic CMV therapy.
S Afr J HIV Med 2012;13(2):68-71.
Methods. From October 2009 to October 2010, voluntarily consenting participants over the age of 15 years with incident clinically diagnosed CMV-R seen at the Dr George Mukhari Hospital ophthalmology clinic were prospectively enrolled in an observational study. Treatment was per clinic protocols and patients were followed up with structured data collection for up to 6 months.
Results. Eight individuals, all HIV infected and 50% female, were identified and enrolled. At enrolment, median age was 38 years (interquartile range (IQR) 32 - 39 years), median CD4 count 20 cells/μl (IQR 13 - 46.5 cells/μl), and 50% were currently receiving ART (mean duration of ART use 18 days, standard deviation (SD) 2.99 days). No participant received systemic ganciclovir, but 6 reported symptom combinations suggesting systemic CMV: shortness of breath (n=3), diarrhoea (n=3) and/or central nervous system complaints (n=3). Ten eyes had visual impairment less than counting fingers at enrolment. Treatment combinations were: ART plus intravitreal ganciclovir (n=5), intravitreal ganciclovir alone (n=2), and ART alone (n=1). Six-month outcomes were: death (n=1), survival (n=6), loss to follow-up (n=3), untraceable (n=1), systemic symptom resolution (4/4), visual acuity deterioration (0/5), and persisting uveitis (2/3).
Conclusion. In the ART era, incident CMV-R appears to be uncommon in this setting. CMV-R may occur within the first 3 weeks after ART initiation. Even in CMV-R patients with suggestive systemic symptoms, 6-month survival is good despite no systemic CMV therapy.
S Afr J HIV Med 2012;13(2):68-71.
Keywords
HIV; cytomegalovirus; treatment
Metrics
Total abstract views: 3125Total article views: 4093
Crossref Citations
1. Cytomegalovirus Viral Load Kinetics in Patients with HIV/AIDS Admitted to a Medical Intensive Care Unit: A Case for Pre-Emptive Therapy
Simnikiwe H. Mayaphi, Marieke Brauer, Daniel M. Morobadi, Ahmad H. Mazanderani, Rendani T. Mafuyeka, Steve A. S. Olorunju, Gregory R. Tintinger, Anton Stoltz, Michael Nevels
PLoS ONE vol: 9 issue: 4 first page: e93702 year: 2014
doi: 10.1371/journal.pone.0093702